Previously, Dr. Basson was Global Head of Translational Medicine (Cardiovascular and Metabolism) at Novartis for 10 years, where he led the team developing new global programmes to translate basic findings into novel therapeutics.
Dr. Basson was previously Global Head of Translational Medicine for the Cardiovascular and Metabolic Therapeutic Areas at Novartis Institutes for Biomedical Research.
At Novartis, he co-led the Cardiovascular Metabolism Disease Area Decision Board, oversaw a leadership of early clinical portfolio through Proof of Concept and supported late phase clinical programs by indication expansion PoC studies and specialised clinical pharmacology and profiling studies.
He has been involved in the development of a number of important and novel medicines for patients with cardiovascular disease, diabetes, and metabolic disorders.
Prior to Novartis, Dr. Basson was a Professor of Cardiology and Internal Medicine at Cornell University Medical College. He obtained an M.Sc. in Physiological Sciences at the University of Oxford and completed an M.D. and Ph.D. at Yale University. Dr. Basson serves as a scientific advisor to various for-profit and non-profit organisations.
Boston Pharmaceuticals is a clinical stage biopharmaceutical company that partners with innovative biotechnology and pharmaceutical companies to acquire drug development candidates.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes